Pacific Northwest Retina

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Macular degeneration7 trials
• Diabetic eye disease1 trial

Phase

• Phase 34 trials
• Phase 22 trials
• Phase 2/31 trial

Status

• Active, not recruiting4 trials
• Recruiting2 trials
• Completed1 trial

Lead sponsor

• Astellas Pharma Global Development, Inc.1 trial
• Boehringer Ingelheim1 trial
• EyeBiotech Ltd.1 trial
• EyePoint Pharmaceuticals, Inc.1 trial
• Kodiak Sciences Inc1 trial
• and 2 more

Running trials

• Recruiting

  A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

  NCT07496567· Phase 2/3· EyeBiotech Ltd.· Source

  Contact: Study Coordinator

• Recruiting

  Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

  NCT06659445· Phase 2· ONL Therapeutics· Source

  Contact: Study Coordinator

• Active, not recruiting

  A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

  NCT06769048· Phase 2· Boehringer Ingelheim· Source

• Active, not recruiting

  A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

  NCT06683742· Phase 3· EyePoint Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

  NCT06556368· Phase 3· Kodiak Sciences Inc· Source

• Active, not recruiting

  A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

  NCT06491914· Phase 3· Regeneron Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration2 recruiting

Closed trials

• Completed

  Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

  NCT05536297· Phase 3· Astellas Pharma Global Development, Inc.· Source